Nuvalent seeks FDA approval of neladalkib for TKI-pretreated advanced ALK-positive NSCLC, leveraging ALKOVE-1 results demonstrating activity in extracranial disease and brain metastases. ALKOVE-1 ...

What advancements for ALK-positive non-small cell lung cancer are on the way, from treating earlier stages of disease to postsurgical options? When Daniel Wilson, a then-34-year-old father and husband ...

Nuvalent submits NDA to US FDA for neladalkib in TKI pre-treated advanced ALK-positive NSCLC: Cambridge, Massachusetts Wednesday, April 8, 2026, 13:00 Hrs [IST] Nuvalent, Inc., a ...

Nuvalent has submitted an NDA to the FDA for neladalkib, a brain-penetrant ALK-selective TKI for pretreated advanced ...

The FDA approved ensartinib (Ensacove) as a first-line treatment for adults with ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), the agency announced on Wednesday.

In a remarkable case of precision oncology and multidisciplinary care, a 45-Year-Old Male diagnosed with advanced Lung Cancer ...

Many lung cancer patients who have never smoked and don't work around toxic chemicals or carcinogens have been found instead to have a defective gene that drives their cancer. Now, an FDA- approved ...

A clinical pathway blends expertise from many providers. The primary goal of a clinical pathway is to produce maximum value at each practice site. Dr Konduri’s institution strongly emphasizes the ...

The goal is to find cures for ALK- positive lung cancer by targeting residual disease that remains after initial treatment. ALK Positive was founded on the principle that funding innovative, ...

OPDIVO is a prescription medicine used in combination with YERVOY as a first treatment to treat adults with cancer of the ...